For immediate release
Singapore, 27 September 2021 – Actxa and KK Women’s and Children’s Hospital (KKH) are carrying out a clinical study to validate a non-invasive blood glucose predictive model on wearable devices with photoplethysmography (PPG) sensors developed by Actxa.
The roles of wrist-worn and in-ear wearables with PPG sensors are constantly evolving. From being a lifestyle device that monitors sports and activities, to a device that monitors a person’s lifestyle well-being and health, foraying into preventive healthcare, particularly for the prevention of chronic diseases. Diabetes has been one of the “silent” chronic diseases, and research has shown that diabetic patients have a two to three-fold higher risk of developing cardiovascular disease. In Singapore and globally, diabetes and cardiovascular diseases are serious health concerns resulting in poor quality of life.
Leveraging on its expertise and knowledge of wrist-worn and in-ear wearables, Actxa has developed a predictive model based on Artificial Intelligence and Machine Learning (AIML) for PPG sensors to monitor blood glucose level non-invasively.
The collaboration with KKH will enable Actxa to externally validate the predictive model developed against an independent population, further improving the model’s diagnostic ability.
Joel Chin, CEO of Actxa, said, “We are excited about this collaboration as the predictive model will be able to facilitate early detection and intervention of diabetes that will make a significant positive impact in the preventive health arena.
It will also provide valuable insights into wearables’ potential in providing continuous and accurate real-time data that can aid patients, whose blood sugar is in the diabetes and pre-diabetes range, to self-manage their disease better and earlier.”
Associate Professor Ang Seng Bin, Head and Senior Consultant, Family Medicine Service, KKH, who is also the principal investigator of this research at KKH, said, “As Singapore’s largest academic medical centre specialising in women’s and children’s health, KKH is committed to improving patient health outcomes. Through this new collaboration, we hope that we can harness the power of technology to make a difference in patients’ lives, especially those with diabetes.”
This clinical study will be carried out jointly by the following Principal Investigators – Associate Professor Ang Seng Bin (KKH), Emeritus Professor Satvinder Singh Dhaliwal (Actxa) and Mr Shi Bohan (Actxa).
Results and findings from this clinical study are to be published in the second half of 2022 in peer-reviewed scientific journals. Actxa will carry out more clinical trials in the near future to provide further clinical evidence for new products.
About Actxa
Headquartered in Singapore, Actxa Pte.Ltd (“Actxa”) was founded in 2015 with the mission to have deep empathy and harness the power of science and data to empower people to lead healthier lives.
At Actxa, we inspire individuals from all walks of life to make proactive moves to live better and healthier.
Leveraging data analytics, artificial intelligence, and machine learning, we create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and non-invasive blood glucose monitoring.
With the help of these insights, Actxa develops applications such as Healthy Living Score (HLS), Actxa Wellness Programme (AWP) and products to empower individuals to manage and improve their own health.
To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.
Good health and happiness go hand-in-hand. Actxa is committed to taking the lead to create Better Moves, Better Lives to better ourselves, the people around us and our community.
For further information, please contact:
Tan Lay Eng Corporate Communications Manager layeng.tan@actxa.com +65 98770406